Home
|Insights
|Apotex Challenges Amgen Cancer Biologic Patent As Obvious

PDF Link

Apotex Challenges Amgen Cancer Biologic Patent As Obvious

Press Coverage | 12.13.17

Attachments

Download Attachment
20171213 Apotex Challenges Amgen Cancer Biologic Patent As Obvious

Contacts

Michael H. Jacobs
Partner
- Washington, D.C.
  - D | +1.202.624.2568
bWphY29ic0Bjcm93ZWxsLmNvbQ==
Deborah H. Yellin
Partner
She/Her/Hers
- Washington, D.C.
  - D | +1.202.624.2947
ZHllbGxpbkBjcm93ZWxsLmNvbQ==
Shannon Lentz
Partner
She/Her/Hers
- Washington, D.C.
  - D | +1.202.624.2897
c2xlbnR6QGNyb3dlbGwuY29t

Insights

Press Coverage | 05.15.25

Former D.C. Bar President Susie Hoffman Among CCE’s Justice Potter Stewart Awardees

Press Coverage | 05.12.25
Contempt Order Worsens Apple's Antitrust Woes
Press Coverage | 05.08.25
Common Mistakes To Avoid When Launching A Hedge Fund
Press Coverage | 05.08.25
DOJ Civil Rights Appellate Leader Joins Crowell & Moring

View All Insights

Subscribe

to the latest insights from our team